

**Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years**

Zhang F, Zheng J, Li Y, Wang G, Wang M, Su Y, Gu J, Li X, Bass D, Chu M, Curtis P, DeRose K, Kurrasch R, Lowe J, Meizlik P, Roth DA.

RMD Open

2022; 8(1):e001669

**ARTICLE IDENTIFIERS**

DOI: 10.1136/rmdopen-2021-001669

PMID: 35428697

PMCID: PMC9014060

**JOURNAL IDENTIFIERS**

LCCN: 2015268513

pISSN: not available

eISSN: 2056-5933

OCLC ID: 904805113

CONS ID: not available

US National Library of Medicine ID: 101662038

This article was identified from a query of the SafetyLit database.